A trial to examine the biological effects of Saruparib (AZD5305) alone, Darolutamide alone, and in combination in patients with newly diagnosed prostate cancer due to have radical prostatectomy.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503691-25-00

Acronym

D9721C00002

Enrollment

Registered

2023-10-11

Start date

2023-12-11

Completion date

Unknown

Last updated

2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newly diagnosed prostate cancer

None listed

Sex/Gender

Male

Age

18 Years to No maximum

Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026